LabCorp is a leading provider of laboratory testing services, focusing on delivering accurate and clinically relevant tests to support healthcare providers. The company develops innovative testing solutions that enhance diagnostic precision and offer additional clinical insights. Its diverse clientele includes physicians, their patients, hospitals, managed care organizations, private employers, military and law enforcement agencies, as well as pharmaceutical and biotechnology firms. By catering to a wide range of healthcare stakeholders, LabCorp plays a crucial role in the medical diagnostics landscape, helping to improve patient care and outcomes through advanced testing technologies.
Prognos Health is a health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables the querying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes, and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.
Circuit Clinical was born from the experiences of a physician conducting clinical research in his busy private practice. From the core belief that patients prefer to learn about clinical research from healthcare providers they trust, came the vision for Circuit Clinical. Since 2015 we've built one of the largest Integrated Research Organizations [IRO] in the US. Our focus on physician and participant engagement gives us a distinct advantage with the identification of motivated participants through direct HIPAA/FDA-compliant Electronic Medical Record (EMR) review. Coupled with our technology products that enhance the participant and physician experience, Circuit Clinical provides our network of more than 1 million patients, our physicians, and our sponsor partners with a new path forward in clinical research.
Getlabs is the leading platform for at-home diagnostics. Healthcare organizations use Getlabs to send mobile phlebotomists to patients’ homes and collect labs, vitals, and advanced diagnostics. By leveraging Getlabs, partners can improve patient adherence and close gaps in care with same-day, nationwide availability. Our team has raised $50M from strategic investors including the two largest diagnostic laboratories in the United States, Labcorp and Quest. Getlabs’ mission is to save lives by expanding access to diagnostics for everyone.
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently, there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that. It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Their proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune cell therapies.
Ovia Health offers a comprehensive maternity and family benefits solution that transforms the way women and families are supported throughout the parenthood journey. The company is formerly known as Ovuline is making healthcare a lifestyle. Its mobile apps, Ovia Fertility and Ovia Pregnancy, have helped millions of women start their families and live healthier lives.
Biospectal is the remote patient monitoring and biosensing software company, developed the OptiBP smartphone app and data platform to empower people worldwide with a medical-grade device integrated directly into their smartphone for instantaneous blood pressure measurement and monitoring, anytime and anywhere. The app runs on a typical smartphone and uses the built-in camera to record and measure a user’s blood flow via their fingertip quickly and easily. A measurement is rendered in approximately 20 seconds — half the time of a typical blood pressure cuff. The company’s proprietary algorithms and optical signal capture methods then transform the captured data into blood pressure values. The Biospectal OptiBP for Android public beta is available now in the US, UK, France, Germany, Spain and Switzerland.
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and the SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms
TrakCel's proven technology integrates and orchestrates every aspect of Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.
Circuit Clinical was born from the experiences of a physician conducting clinical research in his busy private practice. From the core belief that patients prefer to learn about clinical research from healthcare providers they trust, came the vision for Circuit Clinical. Since 2015 we've built one of the largest Integrated Research Organizations [IRO] in the US. Our focus on physician and participant engagement gives us a distinct advantage with the identification of motivated participants through direct HIPAA/FDA-compliant Electronic Medical Record (EMR) review. Coupled with our technology products that enhance the participant and physician experience, Circuit Clinical provides our network of more than 1 million patients, our physicians, and our sponsor partners with a new path forward in clinical research.
Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.
Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.
Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.
Sandstone Diagnostics offers a centrifuge system that provides plasma and serum collection at-home and the point-of-care. It specializes in the fields of clinical diagnostics, home healthcare, and fertility. It was founded in 2012 and headquartered in Pleasanton, California.
Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advance the quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution. Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement.
OmniSeq offers physicians and their patients of the most actionable tumor-profiling information possible. OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory. It endeavors to find the right drug or the right trial for every patient. It also offers NY State CLEP approved assays, including OmniSeq Comprehensive, a 144 gene NGS assay that covers almost all known genetic alterations associated with an FDA-approved targeted therapy or genotype directed clinical trial. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. The company was founded in 2015 and is based in Buffalo, New York.
The Recovery Platform is a substance use specific platform that facilitates and guides physician and patient compliance when practicing MAT (Medicine Assisted Treatment).
Chiltern International Limited, a contract research organization, provides clinical development, scientific services, and collaborative technologies for pharmaceutical and biotech companies.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.
YourBio Health is developing novel products to optimize the interface of diagnostic medicine and the healthcare consumer by dramatically simplifying blood sampling and testing. By eliminating the barriers to the acquisition of critical diagnostic information, Seventh Sense is contributing to the future of informed, effective healthcare delivery and patient participation in their own well-being. The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere. Their proprietary, single-step Touch Activated Phlebotomy™ (TAP™) technology can be combined with a variety of diagnostic assays for rapid results. TAP's revolutionary sampling capabilities may also integrate with analytical systems to vastly improve the patient and clinician experience.
ClearPath Diagnostics offers the Digene Hybrid Capture 2 testing services to test for human papilloma virus (HPV); testing for GC and Chlamydia; diagnostic services for various tissue specimens to health care providers and their patients; supplemental tissue diagnostics services, including immunohistochemistry; and frozen section analysis services.
Sequenom offers genetic analysis products and diagnostic tests for non-invasive prenatal genetic disorders. The company provides a nucleic acid analysis platform that measures genetic target material and variations.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
Ativa Medical is a medical device manufacturing company that is working to make diagnostic test results available in moments, rather than hours and days. The company specializes in the fields of medical device development, point of care diagnostics, microfluidics, and hematology. The company was founded in 2008 and headquartered in Saint Paul, Minnesota.
Bode Technology Group, Inc serves the law enforcement and identification markets and is unique in providing both state-of-the-art human DNA analysis and innovative DNA collection products. The range of Bode’s services include diverse offerings such as high throughput DNA testing services, casework analysis, missing person identification, private and CODIS databanking of convicted offenders or arrestees, as well as paternity and non-forensic identification. Their patented DNA collection systems are in use worldwide for collections of DNA from convicted offenders and arrestees, from crime scenes, as well as from parents and children for genealogy and identification services. Their analysts and their research and development teams are constantly looking for better ways to bring previously unused approaches and technologies into the labs for routine use for analysis of challenging samples – be it bones or aged, decayed tissue. On the strength and experience of their research and development teams and casework analysts, Bode is able to offer worldwide DNA analysis services, consulting, training, and validation services on a customized basis.
Vivify Health delivers, through common and non-proprietary consumer mobile electronics, a cloud-based, device-agnostic, and ecosystem-connected Remote Care Management platform to enable its provider and payer-based customers to impact a great deal of their overarching strategic objectives. Examples include the ability to advance overall population health, optimize patient engagement, reduce unnecessary readmissions, improve patient satisfaction, facilitate expansion of physician practice services, and achieve significant cost avoidance.
Covance Inc. provides early-and late-stage services to the pharmaceutical, biotechnology, and medical device industries. Its early-stage development services include preclinical and clinical pharmacology services. The company's late-stage services include biomarker services to biotech and pharmaceutical customers, with full management of Phase II and III clinical studies. It also provides lab testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is based in Princeton, N.J. Covance, the drug development business of Laboratory Corporation of America Holdings (LabCorp), is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of their broad experience and specialized expertise, they are in a unique position to supply insights that go above and beyond testing -- They have helped pharmaceutical and biotech companies develop each of the top 50 prescription drugs in the marketplace today. They also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services, and a top global provider of Phase III clinical trial management services.
LipoScience is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered.
YourBio Health is developing novel products to optimize the interface of diagnostic medicine and the healthcare consumer by dramatically simplifying blood sampling and testing. By eliminating the barriers to the acquisition of critical diagnostic information, Seventh Sense is contributing to the future of informed, effective healthcare delivery and patient participation in their own well-being. The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere. Their proprietary, single-step Touch Activated Phlebotomy™ (TAP™) technology can be combined with a variety of diagnostic assays for rapid results. TAP's revolutionary sampling capabilities may also integrate with analytical systems to vastly improve the patient and clinician experience.
Performance, Visibility. Simplicity...It's time for a beautiful network. Stateless is transforming network operations for software-centric networking. Tying together deep network understanding with state-of-the-art distributed systems, cloud, data science and gaming expertise, Stateless transforms network visibility, performance and response and helps accelerate the transition to modern network platforms, tying together physical and virtual layers. Focused on the enterprise data center, Stateless currently partners with the world’s leading network and infrastructure vendors (including VMware (VMW), Cisco Systems (CSCO), Cumulus Networks and others) to deliver solutions to some of the world’s largest private data center operators. We’re looking for software and networking engineers in Greater Seattle and the Bay Area with expertise in one or more of the following areas: Distributed Systems, Service Oriented Architecture, Complex Event processing, Functional Programming, Virtualization, Network design and deployment, Network programming, Network troubleshooting, configuration and performance tuning and SDN. Bonus points for experience working with cloud infrastructure (AWS, Azure, OpenStack) or low-level systems software (linux kernel, hypervisors, compilers/language runtimes), complex gaming systems or graphics and computational geometry. For more information visit http://www.statelessnetworks.com/ or follow Stateless on Twitter: @statelessntwrks.see
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. The company's platform enables cancer researchers and care providers to learn from the experience of every patient. Its database platform aggregates and transforms clinical and financial data from electronic medical records (EMRs) and billing systems that provide comprehensive support to the cancer care providers and life science companies. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers, and over 15 of the top therapeutic oncology companies.
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control. SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners. SynapDx's corporate headquarters is located in Lexington, Massachusetts.
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control. SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners. SynapDx's corporate headquarters is located in Lexington, Massachusetts.
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. The company's platform enables cancer researchers and care providers to learn from the experience of every patient. Its database platform aggregates and transforms clinical and financial data from electronic medical records (EMRs) and billing systems that provide comprehensive support to the cancer care providers and life science companies. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers, and over 15 of the top therapeutic oncology companies.
MEDTOX operates a SAMHSA-certified drug testing laboratory, a CAP and CLIA-certified clinical laboratory and a diagnostic division which is an FDA registered establishment. Our comprehensive laboratory and diagnostic testing services coupled with our commitment to excellent customer service ensures that our clients' testing programs operate as efficiently and effectively as possible. We are committed to building strong relationships with our clients; being responsive to their questions and adaptable to their needs.
Monogram is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases.
Tandem Labs is a bioanalytical contract research organization that offers the pharmaceutical and biotechnology companies with assistance in their clinical and preclinical drug development programs. Tandem Labs provides both mass spectrometry and immunochemistry services to support discovery of bioanalytical studies. It also provides GLP LC-MS/MS and immunoanalytical services, biomarker services, LC-MS/MS and immunoanalytical specialized testing services. Tandem Labs was acquired by LabCorp in January 2008. Tandem Labs was founded in 1995 and is based in Salt Lake City, Utah.
Litholink Corp providing the highest level of customer support for our 24-hour urine testing services. Our national infrastructure allows for a seamless, integrated service that makes it easier for clients to manage their laboratory needs.
Dianon Pathology offers a broad array of testing procedures, combining the expertise of an academic-based center with the personal service of a local pathologist. Their services include dermatopathology, gastrointestinal pathology, and uropathology.
Dynacare is an independent clinical laboratory offering services in certain regions of the U.S. and Canada. It operates 26 central laboratories (two of which are esoteric), 115 rapid response labs and 302 patient service centers in 21 states and two Canadian provinces.
Path Lab
Acquisition in 2001
Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity.
ViroMed Laboratories, a member of LabCorp's Specialty Testing Group, is an FDA-registered laboratory that provides infectious disease testing in support of our human cells, tissues and cellular and tissue-based products (HCT/Ps) donor clients.
Allied Clinical Laboratories
Acquisition in 1994
Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.